MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) announced today that data from a large-scale Phase II study of ciclesonide HFA metered-dose inhaler (MDI), a nasal aerosol formulation, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients, were presented at the AAAAI 2008 annual meeting held in Philadelphia, PA. In this study, all doses of ciclesonide HFA (75 mcg, 150 mcg and 300 mcg once-daily) met the primary efficacy endpoint and demonstrated a statistically significant reduction in 24-hour total nasal symptom scores (TNSS) versus placebo. The study also met its secondary endpoint of instantaneous TNSS improvement versus placebo. There were no clinically meaningful differences in the incidences of adverse events (epistaxis, nasal discomfort and headache) between each of the ciclesonide HFA treatment groups and placebo.
